Before building anything, you need an accurate picture of where the gaps are. Not the picture you'd present to an investor — the one that's actually true.

Pull five experiment records from six to twelve months ago, at random. For each one, try to answer these questions without asking anyone and without going to a different system: What specific material lots were used? Did anything deviate from the protocol, and if so, what was the documented response? Who performed each step, and when? Where is the raw data file, and is it still attached to this record?

Time yourself. If any of those questions takes more than three minutes to answer, or if the answer requires calling a scientist who was in the lab that day, you have a traceability gap. Document what you find — not to fix it immediately, but because knowing where the gaps actually are is the only honest starting point for this work.

Document control sounds bureaucratic. It isn't, when you understand what problem it's actually solving. The problem is this: without controlled documents, you cannot prove that the procedure a scientist followed last Tuesday was the approved, current version of that procedure. You can show that a procedure exists. You cannot show which version was active at the time of the experiment.

GMP document control requires, at minimum: a version numbering system, an approval workflow before documents become effective, a mechanism to retire superseded versions so they can't be accidentally used, and a record showing which version was in effect on any given date. None of this needs to be complex. A document management system that logs version history and approval timestamps handles all of it. What doesn't work is a shared drive where documents are overwritten in place, or a system where "approved" means someone said yes in a Slack message.

Start with your SOPs for critical processes. Get those under version control first. Expand from there as capacity allows — but don't let perfect be the enemy of functional. A simple, consistently applied version control system beats a sophisticated one that's used inconsistently every time.

This is the step that gets skipped most often in early-stage labs, and it's the one that causes the most pain in regulatory interactions. The instinct is to track materials at the reagent or product level — "we have Buffer X." GMP traceability requires lot-level tracking. Not Buffer X, but Lot 4872 of Buffer X, received on this date, with this CoA, passing QC on this date, used in these experiments, with this remaining volume, expiring on this date.

The reason lot-level tracking matters is straightforward: when a problem occurs — a failed batch, an unexpected result, a stability concern — the investigation traces back through material inputs. If you can't say with certainty which lot went into which experiment, you cannot bound the scope of the problem. You end up either over-investigating (pulling everything that might have used the suspect material) or under-investigating (missing the actual root cause). Both are expensive.

Start by defining what "a material record" means in your lab. At minimum: lot number, supplier, CoA reference, receipt date, storage condition, QC status, expiry, and a log of which experiments consumed it. That's not a complex record. It's a consistent one — and consistency is what makes it useful under scrutiny.

Free-text experiment records are a liability in regulated environments. Not because they can't contain the right information — often they do. But because they can't be queried, compared, or verified consistently. An auditor reviewing 50 free-text notebook entries for a process development campaign faces a reading comprehension task, not a data review. That's a problem you've created for them, and for yourself.

The solution is templates — but not generic ones. Templates designed at the level of your specific process stages: upstream fermentation, downstream purification, formulation, analytical, stability. Each template defines the required fields, the acceptable data types (numeric, date, dropdown, free text where appropriate), and the structure of outcome capture. When templates are in place, every scientist running the same type of experiment produces structurally identical records. Cross-run comparison becomes a query. Auditor review becomes a data verification exercise rather than a reconstruction effort.

One practical note: building templates feels like overhead until the first time you need to compare 30 runs across a parameter space. Then it feels like the most valuable thing you ever did. The labs that resist templates early almost universally wish they'd done it sooner.

This is where a lot of compliance programs fail in practice, even when they look good on paper. A deviation management system that requires a scientist to open a separate module, fill out a five-field form, select a severity level, and assign a CAPA owner will not be used consistently for minor deviations. Scientists are busy. Minor deviations feel inconsequential. The form feels disproportionate to the event. So it doesn't get filed.

Then, six months later, a pattern of minor deviations that should have been noticed and addressed earlier becomes visible in a batch failure — and every undocumented deviation is now a data integrity question rather than an operational one.

The fix is reducing friction, not increasing enforcement. A deviation note that takes 30 seconds to add within the experiment record itself — not in a separate system — gets completed consistently. "pH exceeded upper limit by 0.3 units at hour 4; continued per supervisor verbal approval; outcome normal" is a compliant deviation record. It doesn't need to be a formal CAPA unless the pattern warrants it. What it needs to be is timely, in-context, and findable later.

21 CFR Part 11 compliance is the regulatory standard that governs electronic records and signatures in FDA-regulated environments. A lot of early-stage labs treat it as a future concern — something to implement when they're closer to the clinic. That's a reasonable prioritization in the abstract. In practice, the labs that wait often find the retrofitting process more painful and more expensive than the original implementation would have been.

The core requirements aren't as complex as the regulation makes them sound: systems must control who can create, modify, and delete records. Changes must be logged with the identity of the person who made them and a timestamp that can't be altered. Electronic signatures must be linked to a specific person and a specific record. Systems must be validated to ensure they perform as intended.

Not every lab needs full Part 11 compliance immediately. But every lab should be using a system that can grow into it — one where access controls are granular, where the audit log is automatic and tamper-evident, and where the path to validation doesn't require replacing the platform.

Everything in the previous six steps can be in place and still have gaps that only become visible under the specific pressure of an audit. The way to find those gaps on your own terms — rather than an auditor's — is a structured mock audit conducted by someone who didn't build the systems.

A good mock audit isn't a documentation review. It's a data trace. Pick a specific batch or experiment campaign. Ask the auditor to trace it completely: from the raw material lots that went in, through each process step, through every deviation and its resolution, to the final analytical results and the decision that was made. Then ask them to do it again for a second batch from a different period, a different scientist, and a different product. Where the trace breaks down is where your infrastructure needs work.

The goal isn't to pass the mock audit. The goal is to find out exactly where the infrastructure is thinner than it needs to be, while there's still time to address it. Labs that run mock audits annually — not just before inspections — build a fundamentally different relationship with their data than labs that don't.